[Myelotoxic action of the new antitumor preparation spirobramin]

Experiments on 110 white noninbred tumor-free rats were made to explore the myelotoxic action of a new antineoplastic drug spirobramine. A single (200 mg/kg) intravenous injection and a course of drug treatment (40 mg/kg 5 times every other day) produced monotypic changes in the peripheral blood and bone marrow hemopoiesis, primarily marked by inhibition of erythroid, eosinophilic and thrombocytic myeloid fibers followed by the development of moderate anemia, thrombocytopenia and aneosinophilia in the peripheral blood. A single injection of spirabramine in an MTD produced more pronounced changes in the blood than injection of the drug in divided doses.